ClinicalTrials.gg
Not yet recruitingNCT07383415PRP-I RCTUpdated Feb 3, 2026

Intranasal Platelet-Rich Plasma With or Without Topical Insulin for Post-Inflammatory Anosmia

An interventional study of Intranasal PRP Plus Topical Insulin and Intranasal PRP Plus Saline (Placebo) in Anosmia and Inflammatory Anosmia, sponsored by Amin Javer. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Amin Javer · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study evaluates whether adding topical insulin to intranasal platelet-rich plasma (PRP) improves smell recovery in adults with post-inflammatory anosmia. Participants will be randomly assigned to receive either intranasal PRP combined with topical insulin or intranasal PRP alone. Changes in olfactory function will be assessed over time to compare the effectiveness and safety of the two treatments.

Read the detailed description

Post-inflammatory anosmia is a common cause of persistent olfactory dysfunction with limited effective treatment options. Platelet-rich plasma (PRP) has been proposed as a regenerative therapy due to its high concentration of growth factors, while topical insulin has demonstrated potential neurotrophic and anti-inflammatory effects in olfactory tissue.

This randomized controlled trial aims to evaluate whether the addition of topical insulin to intranasal PRP provides greater improvement in olfactory function compared with intranasal PRP alone in adults with post-inflammatory anosmia. Participants will be randomly assigned to receive either combined intranasal PRP plus topical insulin or intranasal PRP alone.

Olfactory function will be assessed at baseline and at predefined follow-up time points using validated smell testing methods. Safety and tolerability of the interventions will also be monitored throughout the study. The results of this study will contribute to understanding the potential role of regenerative and neurotrophic therapies in the management of post-inflammatory anosmia

02

Conditions studied

  • Anosmia
  • Inflammatory Anosmia

Browse trials for

Keywords

  • PRP
  • PRP-INSULIN
03

In context

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

This study's planned enrollment of 20 is below the median of 60 across 114 interventional studies indexed under Anosmia.

Browse Anosmia studies →

Lead sponsor

Amin Javer is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with olfactory dysfunction despite olfactory training therapy
  • Loss of smell within the past 5 years
  • Loss of smell occurred after an infection
  • count is over 150,000 platelets per microliter

Exclusion criteria

Exclusion Criteria:

Have a history of or currently have sinonasal tumours Have a history of surgery or radiotherapy for the base of your skull Have been treated with antibiotics in the past month before surgery Have a condition called systemic vasculitis or any bleeding disorder Have a suspected or known allergy to insulin or PRP or Lysate (PL) Have inhaled drugs (i.e cocaine) in the past 6 months of your enrollment Smell loss is due to a head trauma or after surgery Unable to complete the Sniffin Stick Smell test or questionnaires

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    PRP Plus Topical Insulin

    Participants receive intranasal platelet-rich plasma in combination with topical insulin.

    Biological: Intranasal PRP Plus Topical Insulin

  • Placebo comparator
    PRP Alone

    Participants receive intranasal platelet-rich plasma with saline instead of insulin.

    Biological: Intranasal PRP Plus Saline (Placebo)

Interventions

  • BiologicalIntranasal PRP Plus Topical Insulin

    Drug pages: Platelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · InsulinStudies of InsulinInsulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Autologous platelet-rich plasma administered intranasally with the addition of topical insulin applied to the olfactory cleft.

  • BiologicalIntranasal PRP Plus Saline (Placebo)

    Autologous platelet-rich plasma administered intranasally with saline applied in place of topical insulin as a placebo comparator.

06

What researchers measure

Primary outcomes

  1. Change in Olfactory Function

    Change in olfactory function from baseline as measured using a validated smell identification test.

    Time frame: Baseline to 12 months post-intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 9 months is below that.

Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 3, 2026
StartEst.
Mar 30, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jan 1, 2027
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07383415
Lead sponsor
Amin Javer
Responsible party
Amin Javer (MD, St. Paul's Hospital, Canada) — Sponsor-investigator
First posted
Feb 3, 2026
Start date
Mar 30, 2026 (estimated)
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Feb 3, 2026

Study contacts

Amin Javer, MD
Contact
sinusdoc@me.com
604-806-9926

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Platelet rich plasma · Insulin

Start the discussion